awmsg logo



fosfomycin (Fomicyt®)


Reference No. 2710

Publication date:
18/11/2015


Appraisal information

fosfomycin (Fomicyt®) 40 mg/ml powder for solution for infusion


Company: Nordic Pharma UK Ltd
BNF category: Infections
NMG meeting date: 09/09/2015
AWMSG meeting date: 21/10/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3015
Ministerial ratification: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fosfomycin (Fomicyt®) is recommended as an option for use within NHS Wales for the treatment of the following infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract infections; bacterial meningitis; and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Fosfomycin (Fomicyt®) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections listed above, or when these alternative antibacterial agents have failed to demonstrate efficacy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download